NOVARTIS N - Dusseldorf Stock Exchang (NOT DU) stock market data APIs
€104.9577
-0.5(-0.5%)
as of September 16, 2025
Try our APIs with
free plan!
NOVARTIS N - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NOT.DU.
Prev. Close
104.9577
Open
104.4615
High
104.4615
Low
104.9577
52 wk Range
71.5574-111.28
Market Cap
160 075 M
Dividends (Yield)
0.0487
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NOVARTIS N - Dusseldorf Stock Exchang data using free add-ons & libraries
Get NOVARTIS N - Dusseldorf Stock Exchang Fundamental Data
NOVARTIS N - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get NOVARTIS N - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NOVARTIS N - Dusseldorf Stock Exchang News
New
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
Shares of clinical-stage biotech Monte Rosa Therapeutics GLUE rose 44% on Monday after announcing that it had entered into a collaboration deal with pharma giant Novartis NVS to develop novel molecula...
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
Monte Rosa Therapeutics GLUE shares soared 44.1% in the last trading session to close at $6.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This c...
Does the Recent 4.6% Dip Signal Opportunity for Novartis in 2025?
If you are trying to figure out what to do with Novartis stock, you are far from alone. Investors everywhere are wondering whether now is the moment to buy, hold, or look elsewhere, especially with th...
Europe Refractory Epilepsy Treatment Research Report 2025 | Market to More Than Double to Reach $2.82 Billion by 2035, Driven by CBD Growth, Uptake of Neuromodulation Therapies, Strong R&D Pipeline
Company Logo The Europe refractory epilepsy treatment market is anticipated to grow from $1.34 billion in 2024 to $2.82 billion by 2035, with a CAGR of 6.98% from 2025 to 2035. This shift towards per...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
